Latest Content

Sagar S. Patel, MD, discusses data from trials evaluating agents in the Orca platform and where they fit into hematologic malignancy treatment paradigms.

During an Onclive Peer Exchange, panelists examined the utility of ctDNA in bladder cancer and other GU malignancies.

Frontline tislelizumab/chemotherapy yielded sustained PFS outcomes and a meaningful OS improvement vs placebo/chemotherapy in recurrent or metastatic NPC.

Multi-cancer early detection testing has emerged as an exciting strategy to expand cancer screening.

IMPT generated similar physical QOL scores, local disease control, gastronomy tube dependence, and OS vs IMRT in oropharyngeal squamous cell carcinoma.

Ulrich Steidl, MD, PhD, has been named director of the Montefiore Einstein Comprehensive Cancer Center and vice president of cancer medicine at Montefiore Einstein.

Douglas Flora, MD, LSSBB, discusses how AI is helping oncologists keep up with an evolving field, reinvent care timelines, and connect with patients.

Read below to hear from Drs Markman and Slomovitz on the sessions and abstracts they’re looking forward to at this year’s SGO Annual Meeting on Women’s Cancer.

An NDA for neladalkib in TKI-pretreated, advanced, ALK-positive NSCLC was submitted to the FDA.

Low-cost blood tests that detect multiple blood cancers and diseases have been developed by researchers at UCLA Health.

The final analysis of the phase 1/2 BRUIN trial showed consistent stability or improvements in PROs with pirtobrutinib in CLL/SLL and MCL.

Experts highlight ctDNA-guided strategies, ADCs, and targeted therapies shaping CRC research in the first quarter of 2026.

Jan Philipp Bewersdorf, MD, FACP, detailed findings from a meta-analysis and considerations for the use of luspatercept for anemia in lower-risk MDS.